Adverum Biotechnologies Appoints Senior Leaders
“We are excited to have Carol and Jim join our team at Adverum and they both bring important sets of expertise as we expand our medical and financial teams,” said
Dr. Hoang has extensive expertise in ophthalmology, and more than 15 years of industry experience. At Adverum, she will establish and lead all medical affairs activities. Previously, she held a similar role at
Mr. Shahbazian has nearly two decades of experience in the biopharmaceutical industry, and will be responsible for financial operations, including planning, controlling, accounting, and reporting. Previously, Mr. Shahbazian held a similar position with Relypsa/
On the date she commenced her employment with Adverum, the company granted Dr. Hoang a stock option to purchase 140,000 shares of Adverum’s common stock pursuant to the inducement grant exception under Nasdaq Rule 5635(c)(4), as an inducement that is material to Dr. Hoang’s entering into employment with Adverum. The option has a per share exercise price equal to the closing sales price of Adverum’s common stock on the
On the date he commenced his employment with Adverum, the company granted Mr. Shahbazian a stock option to purchase 100,000 shares of Adverum’s common stock, and a restricted stock unit to acquire 9,400 shares of Adverum’s common stock, pursuant to the inducement grant exception under the Nasdaq Stock Market Rule 5635(c)(4), as an inducement that is material to Mr. Shahbazian entering into employment with Adverum. The option has a per share exercise price equal to the closing sales price of Adverum’s common stock on Nasdaq Stock Market on the grant date, and will vest over four years, subject to his continued service with Adverum. The restricted stock unit will vest over eighteen months, subject to his continued service with Adverum.
About Adverum Biotechnologies, Inc.
Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company has collaboration agreements with Regeneron Pharmaceuticals and Editas Medicine. Adverum’s core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control. For more information, please visit www.adverum.com.
Investor and Media Inquiries: Investors:
Amy Figueroa, CFA Investor Relations Consultant email@example.com 650-823-2704 Media: Joshua MansbachSolebury Trout firstname.lastname@example.org 1-646-378-2964
Source: Adverum Biotechnologies, Inc.